Original Research Article

Multidrug resistant clinical strains isolated from tracheal aspirates of patients in Dhaka, Bangladesh

Jinia Afroz¹, Fatema T. Jubyda², Sanzida Sharmin¹, Md. J. Faruq¹, Amit K. Dey², Md. Ibrahim³, Tasmia Farzana¹, Murshed H. Sarkar²*

¹Department of Microbiology, Primeasia University, Dhaka, Bangladesh
²Department of Microbiology, ³Department of Fruits and Food Processing and Preservation, Bangladesh Council of Scientific and Industrial Research (BCSIR), Rajshahi, Bangladesh

Received: 11 January 2020
Revised: 31 January 2020
Accepted: 05 February 2020

*Correspondence:
Dr. Murshed H. Sarkar,
E-mail: murshedhasan-raj@bcsir.gov.bd

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Antimicrobial resistance poses a major threat in the treatment of respiratory disease especially in developing countries like Bangladesh. Multidrug-resistant (MDR) bacteria along with extremely drug resistant (XDR) bacteria have emerged as major clinical and therapeutic dilemma in the treatment of tracheal infections here. Thus, the aim of this study is to assess multidrug resistance among clinical strains isolated from tracheal aspirates of patients in Dhaka, Bangladesh.

Methods: Total 200 clinical isolates from tracheal aspirates were identified and their antibiotic susceptibility profiles were evaluated by using the VITEK 2 system following the Clinical and Laboratory Standards Institute guidelines. Patient information on diagnosis, sex, age was obtained from hospital data.

Results: Of 200 clinical isolates obtained, Pseudomonas aeruginosa was the most frequent pathogens (30.5%) followed by Acinetobacter baumannii (29%), Klebsiella pneumoniae (22.5%), Streptococcus pneumoniae (7.5%), Escherichia coli (5%), Staphylococcus aureus (2%), Proteus spp (1.5%), Enterobacter spp (1%), Citrobacter spp (0.5%), Providencia spp (0.5%). Of 20 different antibiotics tested, highest number of isolates (86%) showed resistance to third generation cephalosporin cefixime, however least number of isolates showed resistance to polymixin antibiotics- colistin (12.5%) and polymixin B (6%). Tracheal infection was found to be more prevalent in males rather than in females although this difference was not statistically significant. The prevalence of infections was highest among the patients of age-group (old adults) ≥60 years (61.5%). Of 200 clinical isolates, 43 (21.5%) were XDR and 125 (62.5%) were MDR bacteria. Of 200 clinical isolates, the synthesis of extended spectrum β-lactamases (ESBL) and carbepenemase were detected in 59 (29.5%) and 98 (49%) strains respectively.

Conclusions: Tracheal infections caused by β-lactamase producing MDR and XDR pathogens among patients are high in Dhaka, Bangladesh. Therefore, there is an urgent need for constant surveillance and interventions in Bangladesh in order to prevent further spreading of those resistant organisms.

Keywords: Tracheal infection, MDR, XDR, β-lactamases

INTRODUCTION

Lower respiratory infections are one of the leading causes of global morbidity and mortality from infectious diseases worldwide.¹ Community acquired pneumonia...
This extensively carbapenemases extended in Enterobacteriaceae MRSA people Staphylococcus (XDR) drug with pneumoniae, studies illness, baumannii, most bacteria bacteria. responsible as CAP, caused to frequency nosocomial pneumonia and acute and chronic bronchial infections in patients with chronic obstructive pulmonary disease (COPD) and bronchiectasis are known as the most common respiratory diseases those are responsible for elevated morbidity and mortality rate. Lower respiratory tract infections like tracheal infections are caused by both of Gram-positive and Gram-negative bacteria. The emergence of multidrug-resistant (MDR) bacteria poses a major threat in hospital settings. The most frequent multidrug-resistant bacteria associated with tracheal infections are *Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii*, and other Enterobacteriaceae.

Antibiotic resistance is an increasingly serious threat to global public health that threatens our ability to treat common infectious diseases, resulting in prolonged illness, disability and death. In recent years, several studies have reported an increased number of bacteria causing both hospital-acquired and community-acquired infections. Enterobacteriaceae including *K. pneumoniae, E. coli* as well as *Enterobacter* spp. along with other bacteria such as *P. aeruginosa* and *A. baumannii* have been identified as major cause of multi-drug resistant (MDR) and extremely drug resistant (XDR) bacterial infections in respiratory tract.

However, Gram-positive organisms such as *Staphylococcus aureus* which is a common causative agent of severe infections in health facilities and in the community become resistant to first-line drugs. Patients infected with methicillin-resistant *Staphylococcus aureus* (MRSA) are estimated to be 64% more likely to die than people with a non-resistant form of the infection whereas MRSA are also reported to cause tracheal infections. For the treatment of life-threatening infections caused by Enterobacteriaceae which are resistant to carbapenems, colistin is used as the last resort of treatment.

However, resistance to colistin has been detected recently in several countries, making infections untreatable those are caused by such bacteria.

Resistance to broad spectrum β-lactams mediated by extended spectrum β-lactamases (ESBL) is a global threat. The emergence of ESBL along with carbapenemases is caused by using β-lactam antibiotics extensively over the last several decades in the clinical practice. New variants of β-lactamases have emerged due to the selective pressure imposed by the use and overuse of new antibiotics in the treatment of patients.

Most ESBL producing organisms are also resistant to aminoglycosides, fluoroquinolones, tetracyclines, chloramphenicol and sulfonamides as they have large plasmids where ESBL genes along with other antimicrobial resistant genes are present.

This study aimed to assess multidrug-resistance among bacteria those are responsible to cause lower respiratory tract infections in Dhaka, Bangladesh to guide treatment protocols along with to determine the existence of ESBL, carbapenemase production in multi-drug and extensively-drug resistant bacterial strains isolated from tracheal aspirates. The data further provides a baseline for future comparative studies.

**METHODS**

The study was conducted between January 2018 and June 2019, in Dhaka Central International Medical College and Hospital in Dhaka, Bangladesh. Of 850 patients attended, 200 patients were suffering from productive coughing, pain below the sternum, short and rapid breathing or chest pain along with fever and headache. Tracheal aspirates specimens (N=200) were aseptically collected from the patients (N=200; Male=133, Female=67) belonging to all age group and both sexes diagnosed with productive coughing, pain below the sternum, short and rapid breathing or chest pain along with fever and headache. Patients who were confirmed to be cases of having asthma and sinusitis were excluded from the study. Tracheal aspirates specimens were subsequently transported to microbiology laboratory of Primasia University for bacterial isolation and identification, phenotypic determination of antibiotic susceptibility, identification of multidrug resistant (MDR), extremely drug resistant (XDR), pan-drug resistant (PDR) organisms along with detection of ESBL and carbapenemase production. Information on diagnosis, sex, age was obtained from patients’ records.

**Bacterial strains**

Of 200 tracheal aspirates, 149 samples showed bacterial growth whereas 51 were sterile. Of 149 samples, total of 200 clinical, non-duplicate bacteria were isolated those were maintained on nutrient agar slants, frozen in lyophilizing medium at -70°C. The identification of bacterial isolates and the evaluation of their antibiotic susceptibility profiles were performed using the VITEK 2 system (bioMérieux, Inc., Hazelwood, MO, United States) following the Clinical and Laboratory Standards Institute guidelines.

Antimicrobial drug susceptibility testing was conducted by Kirby-Bauer method in accordance with the Clinical and Laboratory Standards Institute against penicillins with β-lactamase inhibitors[amoxicillin-clavulanic acid (10 μg), piperacillin-tazobactam (100/10 μg)], cephalosporin [cefuroxime (10 μg), cefixime (5 μg), cefotaxime (30 μg), ceftazidime(30 μg), ceftriaxone (30 μg), cefepime (30 μg)], monobactam [aztreonam(30 μg)], carbapenems [imipenem (10 μg), meropenem(10 μg)], aminoglycosides [gentamicin (10 μg), amikacin(30 μg), netilmicin(10 μg)], fluoroquinolones [ciprofloxacin (5 μg), levofloxacin (5 μg)], folate pathway inhibitor [co trimoxazole (25 μg)], polymyxin [colistin (10 μg), polymyxin B (300U)], glycosylcyclines [tigecyclin. (15 μg)], Methicillin (5 μg) is used only against *S. aureus*. 

*Afroz J et al. Int J Res Med Sci. 2020 Mar;8(3):1094-1102*
Susceptibility to tigecyclin was interpreted using breakpoints proposed by the European Committee on Antimicrobial Susceptibilities Testing (EUCAST).\textsuperscript{15,16} The combination disk test using cefotaxime and ceftazidime, alone and in combination with clavulanic acid was performed in accordance with Clinical and Laboratory Standards Institute guidelines for detection of ESBL.\textsuperscript{(1)} Determination of the production of carbapenemase was carried out by modified Hodge test and imipenem-EDTA disk synergy test as described.\textsuperscript{15,17} MDR, XDR and PDR isolates were identified according to the guidelines recommended by joint initiative of the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC).\textsuperscript{18}

**Statistical analysis**

Data were compiled, tabulated and analyzed in accordance with the objectives of the research. Microsoft Excel spread sheets was used for analyzing the experimental data. Descriptive statistics were reported as frequency along with percentage. The antimicrobial susceptibility of test bacteria was evaluated by a 2-type categorical rating scale as susceptible (antibiotic indicated as fully effective), and resistant (indicated as non-effective). For the testing association between categorical data, Pearson’s chi-square test was used. A two tailed p-value p < 0.05 was considered statistically significant.

**RESULTS**

Of 200 clinical, non-duplicate bacterial isolates obtained, \textit{P. aeruginosa} was the most frequent pathogens (N=61/200, 30.5\%) followed by \textit{A. baumannii} (N=58/200, 29\%), \textit{K. pneumoniae} (N=45/200, 22.5\%), \textit{S. pneumoniae} (N=15/200, 7.5\%), \textit{E. coli} (N=10/200, 5\%), \textit{S. aureus} (N=4/200, 2\%), \textit{Proteus spp.} (N=3/200, 1.5\%), \textit{Enterobacter spp.} (N=2/100, 1\%), \textit{Citrobacter spp.} (1/200, 0.5\%), \textit{Providencia spp.} (N=1/200, 0.5\%) (Table 1 and Figure 1).

**Table 1: Bacterial isolates from tracheal aspirates specimen.**

| Bacterial isolates         | Total number of isolates (N) | Number of isolated organisms (N) (%) |
|---------------------------|-----------------------------|-------------------------------------|
| \textit{Pseudomonas aeruginosa} | 61 (30.5)                  |                                     |
| \textit{Acinetobacter baumannii} | 58 (29)                    |                                     |
| \textit{K. pneumoniae}         | 45 (22.5)                  |                                     |
| \textit{Streptococcus spp.}      | 200 (22.5)                 |                                     |
| \textit{E. coli}            | 15 (7.5)                   |                                     |
| \textit{Staphylococcus spp.}     | 10 (5)                     |                                     |
| \textit{Proteus spp.}         | 4 (2)                      |                                     |
| \textit{Enterobacter spp.}     | 3 (1.5)                    |                                     |
| \textit{Citrobacter spp.}      | 2 (1)                      |                                     |
| \textit{Providencia spp.}     | 1 (0.5)                    |                                     |

![Figure 1: All species causing tracheal infections were showed in the pie chart. The left pie showed six major abundant species, the right pie showed other genera which were not classified to species.](image)

Of 20 different antibiotics tested, highest number of isolates (N=172/200, 86\%) showed resistance to third generation cephalosporin cefixime, however least number of isolates showed resistance to polymixin antibiotics-colistin (N=25/200, 12.5\%) and polymixin B (N=12/200, 6\%) (Table 2).

**Demographic characteristics of patients with bacterial infections**

The patients’ ages ranged between 1 month to 95 years with the gender distribution of 133 (66.5\%) males and 67 (33.5\%) females. The prevalence of infections was...
highest among the patients of age-group (old adults) ≥60 years (N=123/200, 61.5%) followed by middle aged adults (50-59 years) 12% (N=24/200), young adults (30-39 years) 6% (N=12/200), baby (0-2 years) 5.5% (N=11/200), in 3-12 years 5% (N=10/200), in 20-29 years 3.5% (N=7/200). The least prevalence rate (N=2/200, 1%) was found in young adults of age group 13-19 years (Table 3). Tracheal infection was found to be more prevalent in males rather than in females although this difference was not statistically significant (p-value p <0.40). The highest prevalence of infections caused by A. baumannii was in males (N=42/58, 72.4%) than in females (N=16/58, 27.58%). The prevalence of both P. aeruginosa and K. pneumoniae were higher in males (N=38/61, 62.3%; N=30/45, 66.67%) than in females (N=23/61, 37.7%; N=15/45, 33.33%) (Table 4).

**XDR and MDR strains**

Of 200 bacterial isolates obtained from tracheal aspirates, 68% (N=136/200) isolates were MDR whereas 22% (N=43/200) were XDR (Figure 2). Of 61 P. aeruginosa strains tested, 14 (23%) were XDR and 43 (70.4%) were MDR organisms whereas of 58 strains of A. baumannii, 33 (57%) were MDR and 17 (29%) were XDR. Of 45 K. pneumoniae, 32 (71.1%) were MDR and 9 (20%) were XDR (Table 5). For S. pneumoniae, all strains (N=12/15, 80%) were MDR among which 1 strain (7%) was XDR though 1 strain was found to be sensitive to all drugs. Of 10 strains E. coli, 5 strains (50%) were MDR and 2 were XDR (20%). For S. aureus, Proteus spp., Enterobacter spp., Citrobacter spp. and Providencia spp., all strains were found to be MDR (Table 5).

### Table 2: Resistance rate of isolates to different antibiotics.

| Antibiotics                      | Total number of isolates (N) | Susceptible N (%) | Intermediate N (%) | Resistant N (%) |
|----------------------------------|------------------------------|-------------------|-------------------|----------------|
| Penicillins                      |                              |                   |                   |                |
| Penicillin with β-lactamase      |                              |                   |                   |                |
| Inhibitors                       |                              |                   |                   |                |
| Amox/Clav                        | 38 (19)                      | 3 (1.5)           | 159 (79.5)        |                |
| Piperacillin/Tazobactam          | 102 (51)                     | 12 (6)            | 86 (43)           |                |
| Cephalosporins                   |                              |                   |                   |                |
| Second Generation                |                              |                   |                   |                |
| Cefuroxime                       | 32 (32)                      | 6 (3)             | 162 (81)          |                |
| Third Generation                 |                              |                   |                   |                |
| Cefixime                         | 28 (14)                      | 0 (0.0)           | 172 (86)          |                |
| Cefotaxime                       | 36 (18)                      | 5 (2.5)           | 159 (79.5)        |                |
| Ceftriaxime                      | 73 (36.5)                    | 10 (5)            | 117 (58.5)        |                |
| Ceftriazone                      | 40 (20)                      | 7 (3.5)           | 153 (76.5)        |                |
| Fourth Generation                | 200                          |                   |                   |                |
| Cefepime                         | 83 (41.5)                    | 8 (4)             | 109 (54.5)        |                |
| Aminoglycosides                  |                              |                   |                   |                |
| Amikacin                         | 80 (40)                      | 5 (2.5)           | 115 (57.5)        |                |
| Gentamicin                       | 91 (45.5)                    | 0                 | 109 (54.5)        |                |
| Netilmicin                       | 92 (46)                      | 1 (0.5)           | 101 (50.5)        |                |
| Carbapenems                      |                              |                   |                   |                |
| Imipenem                         | 85 (42.5)                    | 3 (1.5)           | 112 (56)          |                |
| Meropenem                        | 92 (46)                      | 1 (0.5)           | 107 (53.5)        |                |
| Monobactams                      |                              |                   |                   |                |
| Aztreonam                        | 49 (24.5)                    | 11 (5.5)          | 140 (70)          |                |
| Fluoroquinolones                 |                              |                   |                   |                |
| Ciprofloxacin                    | 68 (34)                      | 12 (6)            | 120 (60)          |                |
| Levofloxacin                     | 80 (40)                      | 5 (2.5)           | 115 (57.5)        |                |
| Folate Pathway Inhibitors        |                              |                   |                   |                |
| Co-trimoxazole                   | 77 (38.5)                    | 4 (2)             | 119 (59.5)        |                |
| Polymixins                       |                              |                   |                   |                |
| Colistin                         | 173 (86.5)                   | 2 (1)             | 25 (12.5)         |                |
| Polymixin B                      | 188 (94)                     | 0 (0.0)           | 12 (6)            |                |
| Glycelyclines                    |                              |                   |                   |                |
| Tiguecyclin                      | 136 (68)                     | 24 (12)           | 40 (20)           |                |
Table 3: Distribution of different isolates among different age group of patients.

| Age group | No. of patients (N=200) (%) | A. baumannii (N=58) | K. pneumoniae (N=45) | P. aeruginosa (N=61) | S. pneumoniae (N=15) | S. aureus (N=4) | Citrobacter spp. (N=1) | Enterobacter spp. (N=2) | Proteus spp. (N=3) | Providencia spp. (N=1) |
|-----------|--------------------------------|----------------------|----------------------|----------------------|----------------------|------------------|------------------------|------------------------|------------------------|------------------------|
| Baby      | 0-2                            | 11 (5.5)             | 2 (20)               | 2 (4.5)              | 5 (8.2)              | 1 (6.7)          | 0 (0)                  | 0 (0)                  | 0 (0)                  | 0 (0)                  |
| Young Adults | 3-12                           | 10 (5)               | 2 (20)               | 3 (17.3)             | 8 (13.1)             | 4 (26.7)         | 1 (25)                 | 0 (0)                  | 0 (0)                  | 0 (0)                  |
| Mid Adults | 13-19                          | 2 (1)                | 2 (20)               | 3 (6.7)              | 8 (13.1)             | 4 (26.7)         | 1 (25)                 | 0 (0)                  | 0 (0)                  | 0 (0)                  |
| Old Adults | 20-29                          | 7 (3.5)              | 5 (50)               | 34 (75.5)            | 37 (60.7)            | 5 (33.3)         | 2 (50)                 | 1 (100)                | 0 (0)                  | 1 (100)                |
| 80-89     | 11 (5.5)                       | 9 (15.5)             | 1 (10)               | 6 (13.3)             | 11 (18)             | 5 (33.3)         | 1 (25)                 | 0 (0)                  | 1 (50)                 | 0 (0)                  |
| 90-99     | 12 (6)                         | 1 (18)               | 2 (33)               | 3 (50)               | 5 (26)              | 4 (22)           | 2 (20)                 | 0 (0)                  | 0 (0)                  | 0 (0)                  |
| 100+      | 12 (6)                         | 1 (18)               | 2 (33)               | 3 (50)               | 5 (26)              | 4 (22)           | 2 (20)                 | 0 (0)                  | 0 (0)                  | 0 (0)                  |
| Above     | 0 (0)                          | 0 (0)                | 0 (0)                | 0 (0)                | 0 (0)               | 0 (0)            | 0 (0)                  | 0 (0)                  | 0 (0)                  | 0 (0)                  |

Table 4: Distribution of isolates according to the patients’ gender.

| Bacterial isolates (N) | Number of isolated organisms N | Gender | Male | Female |
|------------------------|--------------------------------|--------|------|--------|
| Pseudomonas aeruginosa | 61                             | 38 (62)| 23 (38)|
| Acinetobacter baumannii | 58                             | 42 (72)| 16 (28)|
| K. pneumoniae          | 45                             | 30 (67)| 15 (33)|
| Streptococcus spp.     | 15                             | 7 (47)| 8 (53)|
| E. coli               | 10                             | 9 (90)| 1 (10)|
| Staphylococcus spp.    | 4                              | 3 (75)| 1 (25)|
| Proteus spp.           | 3                              | 1 (33)| 2 (67)|
| Enterobacter spp.      | 2                              | 1 (50)| 1 (50)|
| Citrobacter spp.       | 1                              | 1 (100)| 0 (0)|
| Providencia spp.       | 1                              | 1 (100)| 0 (0)|
| Frequency              | 200                            | 133 (66.5)| 67 (33.5)|

Table 5: Prevalence of MDR and XDR isolates causing tracheal infections.

| Bacterial Isolates (N) | Number of isolated organisms N | No. of MDR organisms N (%) | No. of XDR organisms N (%) |
|------------------------|--------------------------------|-----------------------------|----------------------------|
| Pseudomonas aeruginosa | 61                             | 43 (70.49)                  | 14 (23)                    |
| Acinetobacter baumannii | 58                             | 33 (56.89)                  | 17 (29)                    |
| K. pneumoniae          | 45                             | 32 (71.1)                   | 9 (20)                     |
| Streptococcus spp.     | 15                             | 12 (80)                     | 1 (7)                      |
| E. coli               | 10                             | 5 (50)                      | 2 (20)                     |
| Staphylococcus spp.    | 4                              | 4 (100)                     | 0 (0)                      |
| Proteus spp.           | 3                              | 3 (100)                     | 0 (0)                      |
| Enterobacter spp.      | 2                              | 2 (100)                     | 0 (0)                      |
| Citrobacter spp.       | 1                              | 1 (100)                     | 0 (0)                      |
| Providencia spp.       | 1                              | 1 (100)                     | 0 (0)                      |
| Frequency              | 200                            | 136 (68)                    | 43 (22)                    |

Extended spectrum β-Lactamase (ESBL) and carbapenemase producing strains

Of 200 clinical isolates, the synthesis of ESBL and carbapenemase were detected in 59 (29.5%) and 98 (49%) strains respectively. Of 58 strains of A. baumannii, 28 (48%) and 18 (31%) strains produced carbapenemase and ESBL respectively (Table 6). Of 45 strains of K. pneumonia, carbapenemase and ESBL were detected in 22 (49%) and 16 (36%) strains respectively. Of 10 E. coli strains, 5 (50%) and 3 (30%) strains produced carbapenemase and ESBL respectively. Carbapenemase production was found in S. pneumoniae (N=4/15, 27%), Proteus spp. (N=2/3, 67%), Citrobacter spp. (N=1/1, 100%) and in Providencia spp. (N=1/1, 100%) though no ESBL production was found (Table 6). Most of the
Antibiotics tested were non-effective against ESBL and carbapenemase producer whereas polymixin B, colistin, tigecyclin were found to be effective regimens against ESBL and carbapenemase producers.

| Bacterial isolates (N) | Number of isolated organisms N | Types of β-lactamase production |
|-----------------------|---------------------------------|---------------------------------|
| *Pseudomonas aeruginosa* | 61                              | Carbapenemase | ESBL    |
| 35 (57)                | 22 (36)                         |
| *Acinetobacter baumannii* | 58                             | 28 (48) | 18 (31) |
| 22 (49)                | 16 (36)                         |
| *K. pneumoniae* | 45                              | 4 (27) | 0 (0)   |
| 5 (50)                | 3 (30)                          |
| *Streptococcus spp.* | 15                              | 0 (0)  | 0 (0)   |
| 3 (67)                | 0 (0)                           |
| *E. coli* | 10                              | 5 (50) | 3 (30)  |
| 4 (27)                | 0 (0)                           |
| *Staphylococcus spp.* | 4                               | 0 (0)  | 0 (0)   |
| 2 (67)                | 0 (0)                           |
| *Proteus spp.* | 3                               | 0 (0)  | 0 (0)   |
| 1 (100)               | 0 (0)                           |
| *Enterobacter spp.* | 2                               | 1 (100) | 1 (100) |
| 1 (100)               | 1 (100)                         |
| *Citrobacter spp.* | 1                               | 1 (100) | 1 (100) |
| 1 (100)               | 1 (100)                         |
| Frequency | 200                              | 98 (49) | 59 (29.5) |

Study observed the prevalence of tracheal infections was highest among the patients of old adults whose age was ≥60 years; however least susceptibility to these infections was noticed in young adults of age group 13–19 years. The annual incidence of pneumonia in the elderly people is four-times higher than that of younger populations reported elsewhere.22 Tracheal infection was found to be more prevalent in males rather than in females.

Tracheal infection in patients was caused mainly by *P. aeruginosa* (30.5%) followed by *A. baumannii* (29%). Since *P. aeruginosa* is an opportunist, it can colonize the respiratory tracts after endotracheal intubation or in critically ill and immunocompromised patients, especially in cystic fibrosis patients where it can be aspirated into the lungs.23-25 Tracheal intubation and use of carbapenems are considered as risk factors for patients with *P. aeruginosa* infection.23 A report published in 2016 showed that 33.9% of *P. aeruginosa* were resistant to at least one of the antimicrobial groups under surveillance in Europe.26 Study found 23% strains of *P. aeruginosa* were XDR and 70.4% were MDR organisms.

A. baumannii is an important nosocomial pathogen in healthcare facilities and has become one of the most significant microorganisms causing infections in hospitalized patients in last few decades.27 A study conducted at the Dhaka Medical College Hospital (DMCH) showed 96% strains of *A. baumannii* isolated from endotracheal aspirates collected from patients, were multidrug resistant.28 Another study carried in Square Hospitals Ltd. showed 90% of the *A. baumannii* strains isolated from the patients with lower respiratory tract infections, were multidrug resistant.29 In this study, 57% *A. baumannii* were MDR and 29% were XDR indicating an alarming situation.

DISCUSSION

Antimicrobial resistance (AMR) is a major problem to global public health that requires action across all government sectors and society.5 Infections caused by resistant bacteria responsible for longer duration of illness, additional tests and use of more expensive drugs rather than those infections which are caused by nonresistant bacterial species.5 Epidemiological surveillance of resistance to antibiotics is essential in developing countries like Bangladesh where infections caused by multi-drug resistant bacteria which have resulted in increased morbidity and mortality.19-20 Antibiotic resistance is an increasingly serious threat in Bangladesh which is most likely a result of unrestricted use of antimicrobial drugs.21
The highest incidence rate of respiratory tract infection was caused by *A. baumannii* (25%) followed by *Pseudomonas* spp. (15%) and *Klebsiella* spp. (10%).

Our findings correlate with these reports though *P. aeruginosa* was to be found as a predominate organisms causing respiratory tract infections. It was observed that among 45 strains of *K. pneumoniae*, 71% were MDR and 20% were XDR. *K. pneumoniae* was the most common causative agent of nosocomial pneumonia where the presence of MDR *K. pneumoniae* strains was prevalent. However, other studies showed the most prevalent organism causing tracheal infections was *Enterobacter* spp. followed by *P. aeruginosa*. Though only 1% strains causing tracheal infection were *Enterobacter* spp. in our study, those were multidrug resistant. Moreover, it was observed methicillin resistant *S. aureus* (MRSA) was found to be responsible for tracheal infections. A report stated elsewhere that MRSA is a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia.

Among the Gram-negative bacteria causing chronic respiratory disease, *E. coli* is considered one of the major respiratory threats. Our study showed 20% *E. coli* strains were XDR and 50% were MDR. *S. pneumoniae* is an important causative agent of chronic respiratory disease including tracheal infections that result in higher rate of morbidity and mortality due to MDR *S. pneumoniae*. It was observed 80% strains of *S. pneumoniae* causing tracheal infection were MDR.

The present study observed highest number of strains of both Gram-positive and Gram-negative bacteria showed resistance to third generation cephalosporins, however the most effective antibiotics were polymixin antibiotics especially colistin and polymixin B along with tigecyclin. These findings correlate with other reports where colistin was reported as an effective drug in the treatment of infections caused by MDR bacteria.

In the recent years, antimicrobial resistance mediated by ESBL- and carbapenemase has been found to be ubiquitous and the current dissemination of these enzymes makes it mandatory to understand this phenomenon especially because of the higher mortality, morbidity, and increased health treatment costs associated with resistance to β-lactams. The increasing rate of dissemination of carbapenemase in Bangladesh has been documented with the isolation of clinical *A. baumannii*, *P. aeruginosa* and *K. pneumoniae*.

The present study showed the synthesis of ESBL and carbapenemase were detected in 29.5% and 49% strains respectively where it was noticed most of the antibiotics tested were non-effective against ESBL and carbapenemase producer, however, polymixin B, colistin, tigecyclin were found as effective antibiotics against ESBL and carbapenemase producers.

**CONCLUSION**

The study demonstrated high prevalence of β-lactamase producing multidrug resistant bacteria implicated in the tracheal infections diagnosed among patients. Infections were common among the elderly people and predominantly caused by *P. aeruginosa* followed by *A. baumannii*, *K. pneumonia*, *Streptococcus* spp during the period of our study. Appropriate and justified use of antimicrobial agents should be ensured in controlling the growing danger of antimicrobial drug resistance. Therefore, there is an urgent need for constant surveillance and interventions in Bangladesh in order to prevent further spreading of those resistant organisms. Further studies at molecular level will be required to determine the mechanism(s) of resistance by genotypic methods.

**ACKNOWLEDGEMENTS**

Authors would like to thank all the patients of Dhaka Central International Medical College and Hospital from whom the clinical strains were isolated. Authors would like to thank Bangladesh Council of Scientific and Industrial Research (BCSIR) for the generous support.

**Funding: No funding sources**  
**Conflict of interest: None declared**  
**Ethical approval: The study was approved by the Institutional Ethics Committee from Bangladesh Council of Scientific and Industrial Research (BCSIR), Rajshahi**

**REFERENCES**

1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57:1-134.
2. Rodrigo-Troyano A, Sibila O. The respiratory threat posed by multidrug resistant Gram-negative bacteria. Respirol. 2017;22:1288-99.
3. Agyepong N, Govinden U, Owusu-Ofori A, Essack SY. Multidrug-resistant gram-negative bacterial infections in a teaching hospital in Ghana. Antimicrob Resist Infect Control. 2018;7:37.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1-12.
5. WHO. Antimicrobial Resistance. World Health Organization; 2018. Available at: https://www.who.int/antimicrobial-resistance/en/  
Accessed 2 November 2019.
6. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15:1351-70.
7. De Angelis G, D’Inzeo T, Fiori B, Spanu T, Sganga G. Burden of antibiotic resistant gram negative
bacterial infections: evidence and limits. J Med Microbiol Diagn. 2014;3:1.
8. Rossolini GM, Mantengoli E, Docquier J, Musmanno RA, Corazza G. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains. New Microbiol. 2007;30:332-9.
9. Oduro-Mensah D, Obeng-Nkrumah N, Bonney EY, Oduro-Mensah E, Twum-Danso K, Osei YD, et al. Genetic characterization of TEM-type ESBL-associated antibacterial resistance in Enterobacteriaceae in a tertiary hospital in Ghana. Ann Clin Microbiol Antimicrob. 2016;15:29.
10. Osakabe Y, Tazawa S, Kanasaka S, Narihara K, Takahashi Y. Four cases of airway infections caused by MRSA (meticillin resistant Staphylococcus aureus). Nihon Kyobu Shikkan Gakkai Zasshi. 1990;28:368-73.
11. Hawkey PM, Warren RE, Livermore DM, McNulty CA, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/healthcare Infection Society/british Infection Association Joint Working Party. J Antimicrob Chemother. 2018;73:2-78.
12. Singhal S, Mathur T, Khan S, Upadhyay DJ, Chugh S, Gaind R, et al. Evaluation of methods for AmpC beta-lactamase in gram negative clinical isolates from tertiary care hospitals. Indian J Med Microbiol. 2005;23:120-4.
13. Ansari S, Nepal HP, Gautam R, Shrestha S, Neopane P, Gurung G, et al. Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal. Antimicrob Resist Infect Control. 2015;4:15.
14. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistant threat. Clin Microbiol Rev. 2001;14:933-51.
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-Second informational supplement. M100–S22. The Institute; 2012. Available at: http://zums.ac.ir/files/health/pages/ill/azmayesghah/clsi_2013.pdf. Accessed 15 November 2019.
16. European Committee on Antimicrobial Susceptibility Testing. Susceptibility testing categories S, I and R have been redefined by EUCAST and are now related to exposure of the infecting organism at the site of infection; 2018. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consultation/2018/Information_for_NACs_-_Redefining_antimicrobial_susceptibility_testing_categories.pdf. Accessed 15 November 2019
17. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clini Microbiol Rev. 2007 Jul 1;20(3):440-58.
18. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.
19. Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013;2:31.
20. Hart CA, Kariuki S. Antimicrobial resistance in developing countries. BMJ. 1998;317:647-50.
21. Sack RB, Rahman M, Yunus M, Khan EH. Antimicrobial resistance in organisms causing diarrheal disease. Clin Infect Dis. 1997;24 Suppl 1:S102-5.
22. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis. 2004;4:112-24.
23. Bassetti M, Vena A, Croxatto A, Righi E, Guerry B. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527.
24. West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA. 2002;287:2958-67.
25. Ramphal R, Small PM, Shands JW, FischlSchweiger W, Small PA. Adherence of Pseudomonas aeruginosa to tracheal cells injured by influenza infection or by endotracheal intubation. Infect Immun. 1980;27:614-9.
26. ECDC. Antimicrobial resistance surveillance in Europe 2015. European Centre for Disease Prevention and Control; 2017.
27. Roca Subirà Í, Espinal P, Vila-Farrés X, Vila Estapé J. The Acinetobacter baumanii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Frontiers Microbiol. 2012 Apr 23;3:148.
28. Khatun N, Farzana R, Lopes BS, Shamsuzzaman SM. Molecular characterization and resistance profile of nosocomial Acinetobacter baumannii in intensive care unit of tertiary care hospital in Bangladesh. Bangladesh Med Res Coun Council Bull. 2015;41:101-7.
29. Mannan MA, Kashem MA, Mohammed FR, Rabbani R, Islam MM. Microbiological profile of severe lower respiratory tract infection in intensive care unit of a tertiary care center of Dhaka, Bangladesh. Bangladesh Crit Care J. 2014;2:53-6.
30. Hoque L, Kamal SM, Ahmed Z. Isolation, identification and antimicrobial sensitivity pattern of bacterial isolates from tracheal aspirate of ICU patients of central Dhaka, Bangladesh. Int J Res Appl Nat Soc Sci. 2013;1:11-6.
31. Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, et al. Canadian Critical Care Trials Group. Ventilator-associated pneumonia caused by multidrug-resistant organisms or
Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care. 2008;23:18-26.
32. Khoravi A, Parhizgari N, Montazeri E, Mozaffari A, Abbasi F. The prevalence of bacteria isolated from endotracheal tubes of patients in Golestan Hospital, Ahvaz, Iran, and determination of their antibiotic susceptibility patterns. Jundishapur J Microbiol. 2012;6:67-71.
33. Defres S, Marwick C, Nathwani D. MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia. Eur Respir J. 2009;34:1470-6.
34. Von Baum H, Welte T, Marre R, Suttorp N, Ewig S. CAPNETZ study group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J. 2010;35:598-605.
35. Cilloniz C, Martin-Loeches I, Garcia-Vidal C, San Jose A, Torres A. Microbial etiology of pneumonia: Epidemiology, diagnosis and resistance patterns. Int J Mol Sci. 2016;17:2120.
36. Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007;51:1905-11.
37. Khadgi S, Timilsina U, Shrestha B. Plasmid profiling of multidrug resistant Escherichia coli strains isolated from urinary tract infection patients. Int J Appl Sci Biotechnol. 2013;1:1-4.
38. Ceccarelli D, Alam M, Huq A, Colwell RR. Reduced susceptibility to extended-spectrum β-lactams in Vibrio cholerae isolated in Bangladesh. Front Public Health. 2016;4:231.
39. Pitout JD. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae. Drugs. 2010;70:313-33.
40. Farzana R, Shamsuzzaman SM, Mamun KZ. Isolation and molecular characterization of New Delhi metallo-beta-lactamase-1 producing superbug in Bangladesh. J Infect Dev Ctries. 2013;7:161-8.

Cite this article as: Afroz J, Jubyda FT, Sharmin S, Faruq J, Dey AK, Ibrahim M, et al. Multidrug resistant clinical strains isolated from tracheal aspirates of patients in Dhaka, Bangladesh. Int J Res Med Sci 2020;8:1094-102.